Acoustic neuroma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:23 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Acoustic neuroma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery https://clinicaltrials.eu/trial/study-on-nimodipine-for-hearing-preservation-in-patients-undergoing-acoustic-schwannoma-surgery/ Wed, 29 Apr 2026 14:58:28 +0000 https://clinicaltrials.eu/trial/study-on-nimodipine-for-hearing-preservation-in-patients-undergoing-acoustic-schwannoma-surgery/ This clinical trial is focused on studying the effects of a medication called nimodipine on preserving hearing after surgery for a condition known as vestibular schwannoma, which is also commonly referred to as an acoustic neuroma. This condition involves a non-cancerous growth on the nerve that connects the ear to the brain, which can affect hearing and balance. The treatment being tested is a solution for infusion, meaning it is administered directly into the bloodstream through a vein.

The purpose of the study is to evaluate how effective and safe nimodipine is in maintaining hearing ability after surgery compared to the standard care that patients usually receive. Participants in the study will be randomly assigned to receive either the nimodipine treatment or standard care, which may include a placebo. The study will monitor participants’ hearing function before and after surgery, as well as several months later, to assess any changes or improvements.

Throughout the study, researchers will collect data on the participants’ hearing levels, any changes in their ability to hear, and their overall quality of life. The study will also track any side effects or safety concerns related to the medication, with particular attention to any changes in blood pressure. The trial is expected to continue until March 2026, with participants being followed up for several months after their surgery to gather comprehensive results.

]]>